The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment
Open accessAbstract
The prognosis of early breast cancer (BC) relies on cell autonomous and immune parameters. The impact of the intestinal microbiome on clinical outcome has not yet been evaluated. Shotgun metagenomics was used to determine the composition of the fecal microbiota in 121 specimens from 76 early BC patients, 45 of whom were paired before and after chemotherapy. These patients were enrolled in the CANTO prospective study designed to record the side effects associated with the clinical management of BC. We analyzed associations between baseline or post-chemotherapy fecal microbiota and plasma metabolomics with BC prognosis, as well as with therapy-induced side effects. We examined the clinical relevance of these findings in immunocompetent mice colonized with BC patient microbiota that were subsequently challenged with histo-compatible mouse BC and chemotherapy. We conclude that specific gut commensals that are overabundant in BC patients compared with healthy individuals negatively impact BC prognosis, are modulated by chemotherapy, and may influence weight gain and neurological side effects of BC therapies. These findings obtained in adjuvant and neoadjuvant settings warrant prospective validation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“polychemotherapy and endocrine therapy (such as androgen deprivation) can modulate the alpha and beta diversities of the microbiota, which have been proposed to affect treatment-related adverse events27,28 as well as drug metabolism and efficacy29,30.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“chemotherapy was associated with a substantial shift in the alpha and beta diversity of stool composition in women with breast cancer towards an anti-inflammatory pattern27, entailing a relative under-representation of distinct species commonly found across several pathological disorders (Veillonella parvula, Veillonella atypica, Eggerthella lenta and E. asparagiformis)23.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“B. uniformis, Parabacteroides merdae and Enterocloster spp. were over-represented in stools from women presenting with stage II–III breast cancer (compared with stage I breast cancers), and Bacteroides thetaiotaomicron, E. bolteae and E. clostridioformis were associated with resistance to cytotoxic agents.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This study revealed associations between fecal microbiota and breast cancer staging and neurological side effects 14”
From Impact of the ONCOBIOME network in cancer microbiome research (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredIn the citing paper
“many breast cancer GOMS species (B. uniformis, B. thetaiotaomicron and many members of the Enterocloster genus) were also substantially associated with adjuvant chemotherapy-related neurotoxicity27.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [27]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192 · cited 13×
“Univariate analyses were performed using LEfSe [59] to estimate the”
MethodInfluentialSelf-citationGut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671 · cited 3×
“to immune checkpoint inhibitors [11, 19] (Fig.”
BackgroundSelf-citationGut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 3×
“melanoma [12, 14], kidney [19], and lung [11] cancer.”
BackgroundSelf-citationRichness of human gut microbiome correlates with metabolic markers
Le Chatelier, E., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., Almeida, M., Arumugam, M., Batto, J.-M., Kennedy, S., et al. (2013) · Nature · doi:10.1038/nature12506 · Cited by 4,662 · cited 1×
“processed for rarefaction and normalization and further analysis using the MetaOMineR package [57].”
MethodCommensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 1×
“Such an effect has been achieved with live biotherapeutics in preclinical models [9, 27, 47].”
BackgroundAnticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488
Self-citationThe commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107 · cited 8×
“Accumulating evidence points to the capacity of the intestinal ecosystem, and more specifically specific health-associated bacteria commensals to dampen systemic inflammation [5, 6], to shape the innate and adaptive immune tonus [7–10], and reprogram the tumor microenvironment in tumor bearing mice [11, 12] and patien…”
BackgroundInfluentialDepommier, C., Everard, A., Druart, C., Plovier, H., Van Hul, M., Vieira-Silva, S., Falony, G., Raes, J., Maiter, D., Delzenne, N. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0495-2 · Cited by 2,357 · cited 1×
“muciniphila, and inulin) reduced postprandial glucose levels in type 2 diabetes patients in a randomized double blind placebo controlled trial [48], confirming earlier trials [49].”
ResultBeghini, F., McIver, L. J., Blanco-Míguez, A., Dubois, L., Asnicar, F., Maharjan, S., Mailyan, A., Manghi, P., Scholz, M., Thomas, A. M., et al. (2021) · eLife · doi:10.7554/elife.65088 · Cited by 2,303
Self-citation
Cited by
Bacteria in cancer initiation, promotion and progression
El Tekle, G., & Garrett, W. S. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00594-2 · Cited by 343
Targeting the gut microbiota for cancer therapy
Fernandes, M. R., Aggarwal, P., Costa, R. G. F., Cole, A. M., & Trinchieri, G. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00513-x · Cited by 290
Gut microbiota shapes cancer immunotherapy responses
Lei, W., Zhou, K., Lei, Y., Li, Q., & Zhu, H. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00786-8 · Cited by 194
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
Björk, J. R., Bolte, L. A., Maltez Thomas, A., Lee, K. A., Rossi, N., Wind, T. T., Smit, L. M., Armanini, F., Asnicar, F., Blanco-Miguez, A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02803-3 · Cited by 156
“Recent studies have reported that Eisenbergiella sp., B. wexlerae , C. spiroforme and Erysipelotrichaceae were associated with resistance to ICB 4,36 and enriched in patients with more aggressive tumors 38 .”
Self-citationGut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy
Thomas, A. M., Fidelle, M., Routy, B., Kroemer, G., Wargo, J. A., Segata, N., & Zitvogel, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00785-8 · Cited by 141
Self-citation
Metadata
- Authors
- Terrisse, S., Derosa, L., Iebba, V., Ghiringhelli, F., Vaz-Luis, I., Kroemer, G., Fidelle, M., Christodoulidis, S., Segata, N., Thomas, A. M., Martin, A.-L., Sirven, A., Everhard, S., Aprahamian, F., Nirmalathasan, N., Aarnoutse, R., Smidt, M., Ziemons, J., Caldas, C., Loibl, S., Denkert, C., Durand, S., Iglesias, C., Pietrantonio, F., Routy, B., André, F., Pasolli, E., Delaloge, S., & Zitvogel, L.
- Affiliations
- Université Paris-Sud (FR)
- Inserm (FR)
- Université de Bourgogne (FR)
- Université Paris-Saclay (FR)
- University of Trieste (IT)
- University of Trento (IT)
- UniCancer Group (FR)
- Institut Gustave Roussy (FR)
- Maastricht University (NL)
- University of Cambridge (GB)
- Goethe University Frankfurt (DE)
- Philipps University of Marburg (DE)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Centre Hospitalier de l’Université de Montréal (CA)
- University of Naples Federico II (IT)
- Corresponding author
- Zitvogel, Laurence
- ORCID
- Terrisse, Safae
- Derosa, Lisa
- Iebba, Valerio
- Ghiringhelli, François
- Kroemer, Guido
- Fidelle, Marine
- Christodoulidis, Stergios
- Segata, Nicola
- Thomas, Andrew Maltez
- Martin, Anne-Laure
- Sirven, Aude
- Everhard, Sibille
- Aprahamian, Fanny
- Aarnoutse, Romy
- Smidt, Marjolein
- Ziemons, Janine
- Caldas, Carlos
- Loibl, Sibylle
- Denkert, Carsten
- Pietrantonio, Filippo
- Routy, Bertrand
- André, Fabrice
- Pasolli, Edoardo
- Delaloge, Suzette
- Zitvogel, Laurence
- Venue
- Cell Death & Differentiation
- Published
- 2021-05-07
- Volume
- 28
- Issue
- 9
- Pages
- 2778-2796
- ISSN
- 1350-9047 (ISSN-L)
- 1476-5403
- PMC
- PMC8408230
- OpenAlex
- W3158071568
- Cited by
- 172
- References
- 62
- Citations by year
- 2026: 26 · 2025: 39 · 2024: 25 · 2023: 44 · 2022: 28 · 2021: 9
- FWCI
- 8.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cell Death and Differentiation (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by)
- HAL (submittedVersion, other-oa)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion, cc-by)
- Iris (University of Trento) (submittedVersion, cc-by)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Apollo
- Funders
- Association pour la Recherche sur le Cancer (ANR-18-IDEX-0001)
- Seerave Foundation (ANR-18-IDEX-0001)
- E-Rare
- Cancer Research UK (29567, 16942)
- National Institute for Health and Care Research (NF-SI-0515-10090, NF-SI-0611-10154)
- European Commission (HORIZON2020, 233655)
- Agence Nationale de la Recherche (ANR-10-COHO-0004, UMS3655, 2014-2019, ANR18, ANR-10, E-Rare-2, ANR-16-RHUS-0008, ANR-18-IDEX-0001)
- Fondation Leducq
- Institut National de la Santé et de la Recherche Médicale (UMS3655, Plan Cancer 2014-2019, ANR-18-IDEX-0001)
- Fondation pour la Recherche Médicale (ANR-18-IDEX-0001)
- Ligue Contre le Cancer (ANR-18-IDEX-0001)
- Centre National de la Recherche Scientifique (#ANR-18-IDEX-0001, UMS3655)
- Institut Universitaire de France (ANR-18-IDEX-0001)
- Institut National Du Cancer (#ANR-18-IDEX-0001)
- Institut Gustave-Roussy (UMS3655)
- European Research Area Network on Cardiovascular Diseases
- High-end Foreign Experts Recruitment Plan of China (GDW20171100085)
- Labex Immuno-Oncology ((ANR-18-IDEX-0001))
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- early breast cancer, gut microbiota, fecal microbiota, chemotherapy, treatment side effects, prognosis, plasma metabolomics, gut commensals, xenograft mouse model, adjuvant therapy, neoadjuvant therapy, weight gain, neurological adverse events
- MeSH terms
- Gastrointestinal Microbiome, Breast Neoplasms, Female, Humans, Prognosis, Prospective Studies, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. https://app.cochat.ai/papers/10.1038/s41418-021-00784-1
- The paper
- Terrisse, S., Derosa, L., Iebba, V., Ghiringhelli, F., Vaz-Luis, I., Kroemer, G., Fidelle, M., Christodoulidis, S., Segata, N., Thomas, A. M., Martin, A.-L., Sirven, A., Everhard, S., Aprahamian, F., Nirmalathasan, N., Aarnoutse, R., Smidt, M., Ziemons, J., Caldas, C., . . . Zitvogel, L. (2021). Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. Cell Death & Differentiation. https://doi.org/10.1038/s41418-021-00784-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.